Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

The presentation of Japanese drugmaker Takeda’s latest financial results were presented Thursday, though they took a back ...

Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth & Launch ...

The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who plans to retire in June next year.

In a long-term succession plan, the board of directors at Japan’s largest drugmaker Takeda has made the decision unanimously ...

Suffolk, one of the largest and most innovative real estate and construction enterprises in the country, recently celebrated topping off 585 Kendall. Designed by CBT Architects, 585 Kendall is a mixed ...

NET PROFIT FORECAST: Takeda is expected to post a 59% drop in net profit to 43.58 billion yen, equivalent to $280.2 million, for the three months ended Dec. 31, according to a poll of analysts by data ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance ...

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. This week, the medicine, first approved in 2009, was listed as discontinued on the ...

Takeda (TAK) announced that its board of directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S.

Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year succession process ...